Document is current
Any future updates will be listed below
-
Authors
Shiha, Gamal
Soliman, Reham
Elbasiony, Mohamed
Darwish, Noureldien H. E.
Mousa, Shaker A.
-
Funding
Funding for this research was provided by:
Egyptian Liver Research Institute and Hospital
Virothera Pharmaceuticals
- License Information
-
More Information
Article History
Received: 11 February 2020
Accepted: 9 February 2021
First Online: 25 February 2021
Competing interests
: Gamal Shiha has been a Principal Investigator for Gilead and Abbvie. Reham Soliman has been an Investigator for Gilead and Abbvie. Mohamed Elbasiony has been an Investigator for Gilead. Shaker A Mousa has no conflict of interest other than helping HCV patients in underdeveloped countries have access to treatment at low to no cost. Noureldien H. E. Darwish declares no competing interests.
